Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.36 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.32 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15492445 | 0.89 | ALDH1A1 (0.37) | SMN1; SMN2MEN1ALDH1A1LMNAALOX12 | |
| SCHEMBL11117598 | 0.83 | LIPA (0.42) | SMN1; SMN2MEN1ALDH1A1LMNAALOX12 | |
| SCHEMBL12996988 | 0.78 | SMN1; SMN2 (0.41) | SMN1; SMN2MEN1ALDH1A1LMNAALOX12 | |
| SCHEMBL22111281 | 0.78 | KMT2A (0.45) | SMN1; SMN2MEN1ALDH1A1LMNAALOX12 | |
| SCHEMBL17238842 | 0.76 | TET2 (0.46) | SMN1; SMN2MEN1ALDH1A1LMNAALOX12 | |
| SCHEMBL13997926 | 0.75 | SMN1; SMN2 (0.39) | SMN1; SMN2MEN1ALDH1A1LMNAALOX12 | |
| SCHEMBL13997881 | 0.75 | SMN1; SMN2 (0.39) | SMN1; SMN2MEN1ALDH1A1LMNAALOX12 | |
| SCHEMBL6483909 | 0.75 | KMT2A (0.41) | SMN1; SMN2MEN1ALDH1A1LMNAALOX12 | |
| SCHEMBL28753364 | 0.75 | ALDH1A1 (0.36) | SMN1; SMN2MEN1ALDH1A1LMNAALOX12 | |
| SCHEMBL4639751 | 0.74 | SMN1; SMN2 (0.39) | SMN1; SMN2MEN1ALDH1A1LMNAALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 302 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3006547-B1 | FRAGRANCE-CONTAINING CAPSULE AND COSMETIC IN WHICH SAID CAPSULES ARE BLENDED | SHISEIDO CO LTD (JP) | 2019-10-30 | — | — | EP | claimed |
| US-20160106637-A1 | FRAGRANCE-CONTAINING CAPSULE AND COSMETIC IN WHICH SAID CAPSULES ARE BLENDED | SHISEIDO COMPANY, LTD. (JP) | 2016-04-21 | — | — | US | claimed |
| EP-3006547-A1 | FRAGRANCE-CONTAINING CAPSULE AND COSMETIC IN WHICH SAID CAPSULES ARE BLENDED | Shiseido Company Ltd. (JP) | 2016-04-13 | — | — | EP | claimed |
| EP-2020225-B1 | Fragrance composition | KAO CORP (JP) | 2014-10-08 | — | — | EP | claimed |
| EP-2020225-A2 | Fragrance composition | Kao Corporation (JP) | 2009-02-04 | — | — | EP | claimed |
| US-7332462-B2 | Malodor counteractant compounds | GIVAUDAN SA (CH) | 2008-02-19 | — | — | US | claimed |
| US-7288507-B2 | Malodor counteractant compounds | GIVAUDAN SA (CH) | 2007-10-30 | — | — | US | claimed |
| US-20070116655-A1 | MALODOR COUNTERACTANT COMPOUNDS | GIVAUDAN SA (CH) | 2007-05-24 | — | — | US | claimed |
| US-20060034789-A1 | Malodor counteractant compounds | GIVAUDAN SA (CH) | 2006-02-16 | — | — | US | claimed |
| US-20050245407-A1 | Fragrance composition | KAO CORPORATION (JP) | 2005-11-03 | — | — | US | claimed |
| EP-1552814-A1 | FRAGRANCE COMPOSITION | Kao Corporation (JP) | 2005-07-13 | — | — | EP | claimed |
| US-20040248762-A1 | Malodor counteractant compositions | MCGEE THOMAS (US) | 2004-12-09 | — | — | US | claimed |
| EP-1345883-A1 | MALODOR COUNTERACTANT COMPOSITIONS | Givaudan SA (CH) | 2003-09-24 | — | — | EP | claimed |
| US-20030008787-A1 | Malodor counteractant compositions | GIVAUDAN SA | 2003-01-09 | — | — | US | claimed |
| WO-2002051788-A1 | MALODOR COUNTERACTANT COMPOSITIONS | GIVAUDAN SA (CH) | 2002-07-04 | — | — | WO | claimed |
| US-4009253-A | 4-CYCLOHEXYL-4-METHYL-2-PENTANONE USEFUL AS A MALODOR COUNTERACTANT | MONSANTO COMPANY (US) | 1977-02-22 | — | — | US | claimed |
| EP-4687810-A1 | PREPARATIONS COMPRISING HYDROXY PINACOLONE RETINOATE | Symrise AG (DE) | 2026-02-11 | — | — | EP | disclosed |
| US-12416114-B2 | Fabric spray containing lactilol for malodour reduction | CONIPCO, INC. (US) | 2025-09-16 | — | — | US | disclosed |
| US-4009253-A | 4-CYCLOHEXYL-4-METHYL-2-PENTANONE USEFUL AS A MALODOR COUNTERACTANT | MONSANTO COMPANY (US) | 1977-02-22 | — | — | US | disclosed |
| US-4009253-A | 4-CYCLOHEXYL-4-METHYL-2-PENTANONE USEFUL AS A MALODOR COUNTERACTANT | MONSANTO COMPANY (US) | 1977-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248762-A1 | Malodor counteractant compositions | MAL2, OPRM1, OR51E2 | SMN1; SMN2 502/4885MEN1 1574/4885ALDH1A1 408/4885 |
| US-20060034789-A1 | Malodor counteractant compounds | MAL2, OR51E2, OPRM1 | SMN1; SMN2 732/4885MEN1 1359/4885ALDH1A1 324/4885 |
| US-20070116655-A1 | MALODOR COUNTERACTANT COMPOUNDS | MAL2, OR51E2, OPRM1 | SMN1; SMN2 775/4885MEN1 1275/4885ALDH1A1 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.